Through their lens: Charlotte Hayward has brains on her mind, and her face

This summer we’re sponsoring high school interns in stem cell labs throughout California. We asked those students to contribute to our Instagram photos and YouTube videos about life in the lab, and write about their experiences. 

Charlotte Hayward is a Santa Barbara High School student who is doing a stem cell research internship this summer in the laboratory of Tod Kippin at the University of California, Santa Barbara

In the last six weeks I have come to realize that I have been given a once in a lifetime opportunity. This program caught my attention as soon as I heard about it. I mean, how many opportunities do high school students have to do innovative and groundbreaking research? Well, in case you are unaware, not very many. Just the thought of doing stem cell research during my free time this summer sounded like a dream, but after having experienced it I can truly say it exceeded my expectations.

My project focused on studying how stress on expectant mothers later affects the neural stem cell system and behavior of their offspring. We primarily worked with rats in conducting our research, and let me tell you that was the biggest learning experience of all.

On the first day I was a little apprehensive of conducting animal research, however after experiencing it firsthand and discovering the significance of my project, I have an entirely new view of it. Each day was entirely new and exciting, I felt continuously interested and challenged. On a day to day basis you could find me doing anything from running locomotor activity tests to doing profusions.

Everyday I walked into the lab, slipped on my black nitrile gloves, and got to work. Time flew by and before I knew it the day was done, and I would go home thinking about the exciting things to come the next day.

The people in my lab were so fun and refreshing to be around and I could tell they were really passionate about what they were doing. It was wonderful to see people who have chosen to dedicate their lives to research.

In conclusion I would like to tell you a story about one night during the first week of my research. I walked into the house tired but stimulated by all the work I had done and said to my dad, “I got some brain matter on my face today!”. Of course my dad thought I was crazy, but I thought it was the coolest thing I had ever done. I was experiencing things entirely new and so exciting to me, and that is the most valuable thing I could ever ask for. This program offered me more than I had ever imagined and made me even more excited about all the academic opportunities still ahead of me.

Charlotte Hayward

Charlotte sent us this video of her experience:

2 thoughts on “Through their lens: Charlotte Hayward has brains on her mind, and her face

  1. How Two Guys From Queens Are Changing Drug Discovery

    They have, and then some. Against the grain of industry trends, the company has found ways to create effective new treatments on bargain budgets. According to a FORBES analysis of 220 drugs approved over the past decade for publicly traded companies, the companies that invented 3 or more medicines spent an average $4.3 billion in R&D per drug. The big boys spend still more: $5.5 billion for Merck, $7.8 billion for Pfizer and $10 billion for Sanofi, Regeneron’s partner on many of its projects. Regeneron’s cost per drug? Only $736 million. “He’s been successful beyond anything I could imagine,” says Fred Alt, the Harvard Medical School geneticist who first told Schleifer about Yancopoulos.

    http://www.forbes.com/sites/matthewherper/2013/08/14/how-two-guys-from-queens-are-changing-drug-discovery/

  2. Safety First? How the Current Drug Approval System Lets Some Patients Down

    Andrew Culliford, whose story is featured in the Daily Mail, is one of the estimated 7 in 100,000 people living with Motor Neuron disease, a progressive degenerative disease which attacks muscles, leaving those affected eventually unable even to breathe unassisted. For Andrew, a young father who has a severe form of the disease, it means a two to five year life expectancy.

    Like Les Halpin and Jenn McNary, the mother of twins afflicted with a similar rare disease, he has a simple request: earlier access to medicines that might help improve or extend his life.

    The US introduced a mandatory pre-approval process for pharmaceutical drugs after over 100 people were killed by an untested drug formulation . Today, each drug must go through a series of strictly controlled trials, including Phase 1 tests on healthy volunteers, followed by Phases 2 and 3 which test the drug and dosages on smaller and then larger patient groups. The process is estimated to cost $500 million per drug and to take 8 – 12 years.

    But it has been a failure for one small group of patients: those with rare, imminently lethal diseases, for whom there are no existing good treatments. Those who will die in less than 8 years. It is these patients who are asking to have access to untested medicines, and to avoid placebo controlled trials, where half the participants are given no drug at all. Les has proposed innovative methods of patient recording data. I have discussed this proposal previously on this blog , and in a joint paper with Les Halpin and clinicians.

    http://blog.practicalethics.ox.ac.uk/2013/08/safety-first-how-the-current-drug-approval-system-lets-some-patients-down/

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.